In today’s multiethnic society, genetic disorders previously confined to specific ethnic groups now occur at increasing frequency in broader populations. Based on assumptions about prevalence, traditional carrier screening only targets single gene disorders, according to ancestry or family history. It may not accurately reflect these changing frequencies. Expanded carrier screening by next-generation sequencing (NGS) enables rapid carrier screening research and genetic analysis across a broader range of disorders, crossing ancestries and geographic regions, with a highly accurate and scalable, cost-effective solution.
Hear what your peers are saying about NGS and expanded carrier screening research:
The Role of Pan-Ethnic Expanded Carrier Screening for Inheritable Conditions
Enable educated family planning
Follow the evolution of genetic screening technology, with focus on the advantages of NGS for screening a broad range of inheritable genetic disorders. Review cases that highlight the benefits of expanded carrier screening, identify risks for heritable conditions, and empower real patients with knowledge to make informed decisions.
Dr. Haywood Brown
Professor of Obstetrics-Gynecology and Associate Dean, Diversity Morsani College of Medicine, University of South Florida
Executive Medical Director, Access to Expanded Carrier Screening Coalition
Expanded Carrier Screening: A General Overview
Uncover hidden genetic insights
Review benefits of utilizing expanded carrier screening and guidelines to consider in developing ECS content and reporting. Deep dive into several interesting Mayo Clinic case studies, illustrating the capabilities and complexities ECS.
Dr Linda Hasadsri
Co-Director, Genomics Laboratory, Mayo Clinic
The Increasing Use of Carrier Screening in Fertility Clinics
Alter clinical practice and IVF outcomes
Learn about probabilities of genetic variants and the benefits and challenges of carrier screening and screening technologies. Understand why screening is advantageous in family planning, who should be offered screening, and what should be screened for.
Dr. Dagan Wells
Associate Professor, Nuffield Department of Women’s and Reproductive Health, University of Oxford
Director, Juno Genetics